Said another way, the satiety-promoting effects of psyllium may naturally reduce overall calorie intake without the effort of restriction
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
The Gila Monster and the Billion-Dollar Molecule How a desert lizards venom, ignored by every major pharmaceutical company for nearly a decade, became the template for the worlds most-prescribed weight-loss drugs
and it quickly degrades if not kept frozen
FDA found no evidence supporting the nominated subcutaneous route
SSRIs, selective serotonin reuptake inhibitors
